108 results about "Antitoxin" patented technology

The invention relates to a stable recombinant expression plasmid vector comprising a fragment of polynucleotide encoding a recombinant antitoxin gene. The polynucleotide expresses a polypeptide used for neutralizing toxic polypeptide of a host cell. The toxic polypeptide is expressed in a host cell by a fragment of polynucleotide encoding a toxin gene. The recombinant expression plasmid vector also comprises a fragment of polynucleotide encoding polypeptide expression product. The stable recombinant expression plasmid vector is derived by replicable frame plasmid in Hafnia alvei. The invention also discloses a transformant of the stable recombinant expression plasmid, a method for preparing bio-based pentanediamine by using the transformant, and bio-based pentanediamine prepared with the method provided by the invention. The invention also discloses polyamide and a composition containing polyamide, which are prepared by using the bio-based pentanediamine prepared with the method as a raw material. The invention also discloses a method for preparing pentamethylene-1,5-diisocyanate. The method comprises the steps that: bio-based pentanediamine is prepared by using the method provided by the invention; and the bio-based pentanediamine is transformed into pentamethylene-1,5-diisocyanate.

A method of identifying a molecule capable of inducing death of a bacterial cell which includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules, and identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and said toxin polypeptides, thereby identifying the molecule capable of inducing death of the bacterial cell.

The present invention provides compositions and method for regulating cellular growth and metabolism, intra- and extracellular enzymatic activities, and synthesis of endogenous and/or heterologous proteins, comprising the steps of cloning genes encoding an mRNA interferase (toxin) and its cognate antitoxin; expressing these proteins in a host cell from two separate constitutive or inducible promoters on one or more plasmid vectors or on a chromosome; and regulating the cellular growth and metabolism by controlling the ratio of toxin and antitoxin present in the host cell. Optionally, the method provides further steps of modifying an endogenous or heterologous gene of interest to substitute all mRNA recognition sequences with sequences that are not cleavable by the mRNA interferase being expressed without any change in the amino acid sequence of the protein encoded by the gene; and co-expressing the gene of interest in the same host cell.

The invention provides a bacterial traceless genetic manipulation vector. The vector contains a toxin inverse-screening element controlled by an antitoxin switch and an antibiotics resistance gene. The invention also provides a construction method of the vector and a method for application of the vector in bacterial traceless gene knock-out, knock-in, replacement, point mutation and insertion and deletion of large DNA fragments (larger than 194kb). By the utilization of a constitutive promoter for continuous expression of toxin protein and by the utilization of an inducible promoter for inducible expression of antitoxin protein, the toxin inverse-screening element (TCCRAS) controlled by the antitoxin switch is established, and the problem that specificity of existing genetic manipulation systems of gram-positive bacterium is not high, the systems are instable and screening is difficult is solved.

The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp. or coccidia sp based diseases or other enteric diseases or by generally improving gastro intestinal health or function

The invention discloses a method for preparing an anti-type A botulinum neurotoxin immunoglobulin antibody, which comprises the steps of preparing and obtaining the anti-type A botulinum neurotoxin immunoglobulin antibody through taking type A botulinum neurotoxin recombinant protein rAHc as immunogen to immunize animals. The method for preparing the anti-type A botulinum neurotoxin immunoglobulin antibody eliminates a Fc segment in the antibody which can cause side effect and obtains the horse anti-type A botulinum neurotoxin immunoglobulin F(ab')2 antibody; after blood serum obtained by pentalogy hyper-immune and hexalogy hyper-immune are mixed, the content (purity) of F(ab')2 of the antibody can achieve 80.2 percent in a semi-finished product obtained through further purification; the titer of the antibody can achieve 8000 IU/ml; the antibody has good specificity and sensitivity to type A botulinum neurotoxin; and the purity and the specific activity of the antibody are higher than the antitoxin prepared from the traditional toxin immunity horses. Moreover, the invention has the good stability and safety.

The invention relates to a veterinary medicine for treating poultry bacterial diseases, viral diseases and mixed infection and preparation method thereof, prepared by the following components by weight parts: 300-400 parts of honeysuckle, 300-400 parts of scutellaria, 700-800 parts of fructus forsythiae, 0.5-1.5 parts of ceftiofur, 0.5-1.0 parts of synergist, 20-30 parts of bacteriostatic factor, 5-15 parts of dissolution factor. The veterinary medicine is capable of clearing away the heat-evil and expelling superficial evils and dispelling wind and cooling blood with strong antibiotic, antivirus, antitoxin function and quickly activating immune organ and adjusting immunologic function and recovering all kinds of physiological functions and thoroughly killing grey pathogen, and being equipped with the synergist to enlarge antibacterial spectrum and bactericidal power therefore the curative effect is obviously reinforced.

The invention relates to a preparation method of an antitoxin suitable for high pressure conversion. An antitoxin carrier is the improvement of spherical activated alumina production by a quick dehydration method, so that the antitoxin carrier is converted into a spherical gahnite carrier; and the method of Patent ZL200610125452.8 is used for impregnation in order to obtain the antitoxin. The antitoxin can be used for protecting the cobalt-molybdenum carbon monoxide sulfur resistance conversion catalyst in the carbon monoxide conversion technique under the pressure greater than 3.0 MPa. The high pressure resistance of the antitoxin is superior to that in Patent ZL200610125452.8, and the antitoxic activity and cost are superior to those of the antitoxin using magnesia alumina spinel as the carrier in traditional mixed-grinding band extrusion.

The invention belongs to the field of veterinary medicine, and particularly relates to a compound rifaximin dry suspension for preventing and treating the endometritis of livestock and a preparation method for the same. The rifaximin and sodium new houttuyfonate dry suspension is obtained by using rifaximin and sodium new houttuyfonate as active ingredients, and preparing with pharmaceutically acceptable auxiliary materials. The preparation method comprises the following steps of: performing superfine crushing treatment on raw materials at first; uniformly mixing the treated rifaximin and sodium new houttuyfonate with right amount of filler, suspending aid, surfactant, lubricant, adsorbent and pH buffer according to an equivalent incremental mixing method; subpackaging and sterilizing for1 hour by flowing steam at 100 DEG C. Rifaximin is a novel rifamycin board-spectrum semisynthetic antibiotic medicine, with the advantages of board-spectrum antibacterium, antitoxin and the like, andcapable of preventing and treating the endometritis of dairy cow well; and sodium new houttuyfonate is antibacterial, anti-inflammatory and capable of enhancing immunity as well as resisting bacteriaand diminishing inflammation by cooperating with rifaximin, and has great effect of preventing and treating the endometritis of dairy cow.

The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

A health product with bee products as material comprises the following weight ratio materials: honey 15 to 20, bee pollen 40 to 50, honeycomb 20 to 30, beeswax 6 to 10, propolis 0.5 to 1.5; the beneficial effects is: the products of the present invention has health care beauty, can therapy gastrointestinal dysfunction, endocrine imbalance, adjust nerve balance, anti radiation, antimicrobial, anti-inflammatory and analgesic, antitoxin, stasis-resolving, support various nutrition, has hematopoietic function, improve cell regeneration, promote immunity function of human body obviously, soften blood vessel, brain-health and refresh, promote brain cell growth etc.

The invention provides a preparation method for an immobilization particle used for reducing activated sludge. The preparation method comprises the following steps: uniformly mixing fermentation broths of corresponding strains according to a weight ratio of Bacillus subtilis to Bacillus cereus to Bacillus megaterium to Bacillus licheniformis to Bacillus pumilus of 4-6: 4-6: 6-9: 5-7: 4; preparing bacterial powder from the above mentioned mixed bacterial liquid through spray drying; and preparing the immobilization particle by using a PVA-saturated boric acid method. By using an immobilization method, high-efficiency sludge degrading bacterial strains are embedded, so the concentration of the sludge degrading bacterial strains participating in a reaction can be greatly increased, the bacterial strains are vulnerable to loss and dying, have longer action time and obviously improved antitoxin capability and tolerance, solid-liquid separation can be easily realized, and secondary pollution is small.

Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.

The invention discloses a humanized single-chain antibody 8B of clostridium perfringens alpha-toxin. The humanized single-chain antibody 8B is screened from a phage antibody library Source bioscience, is a full-humanized antibody of the clostridium perfringens alpha-toxin and can be used for achieving a toxin neutralization treating effect, overcoming various side effects of a heterologous antibody and eliminating complex steps and high cost of humanization modification on the heterologous antibody; and the single-chain antibody is small in molecular weight, strong in in-vivo penetrability and capable of rapidly reaching to damaged tissues and cells to exert an antitoxin effect, so that the double aims of economy and high efficiency are achieved. The alpha-toxin has a certain homology with other types of toxins of clostridium perfringens, so that the antibody drug possibly generates inhibiting and treating effects for other types of toxins and can also be used as a detecting reagent to detect the clostridium perfringens alpha-toxin.

The present invention encompasses recombinant bacteria suitable for live attenuated vaccines, and methods of use thereof. One aspect of the present invention encompasses a recombinant Salmonella bacterium. The bacterium comprises a first promoter operably linked to a nucleic acid encoding a toxin and a second promoter operably linked to a nucleic acid encoding an antitoxin, wherein the second promoter is inactive in vivo, but active in vitro.

The invention provides a novel method for producing an antitoxic nonwoven fabric by molecularly grafting the antitoxic molecule thereto. The method comprises immersing a fibrous media comprising a material having a melt flow index of less than 150 MFI in a stable antitoxin solution comprising an antitoxin, preferably triiodide. The wet media is processed through rollers, thereby forcing the antitoxic molecule (e.g., iodine) to penetrate the media. The wet media is dried, and the fabric isolated therefrom. The invention further provides products incorporating the antitoxic media formed by this molecularly grafting method, including a wound dressing, surgical drape, privacy curtain, facemask, gown, article of protective clothing, shoe covering, hair covering, air filter, medical tape, and wipe.

A process for preparing house antiserum (antitoxin) for preventing the anaphylactic reaction caused by foreign protein and the serum disease includes such steps as digesting the immune plasma, ammonium sulfate depositing twice, alum-adsorbing deposition, ultrafiltering, concentrating and adsorptive purifying by chromatography by ion exchange column.